190 related articles for article (PubMed ID: 28075663)
1. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.
Ding L; Zhang Z; Xu Y; Zhang Y
Bioengineered; 2017 Jul; 8(4):383-392. PubMed ID: 28075663
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.
Bassarova AV; Nesland JM; Sedloev T; Lilleby W; Hristova SL; Trifonov DY; Torlakovic E
Int J Surg Pathol; 2005 Jul; 13(3):239-46. PubMed ID: 16086078
[TBL] [Abstract][Full Text] [Related]
3. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
[TBL] [Abstract][Full Text] [Related]
4. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China.
Wang RJ; Lu LJ; Jin LB; Li HY; Ren GS; Wu KN; Liu SC; Kong LQ
Med Oncol; 2014 Jan; 31(1):788. PubMed ID: 24338167
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
9. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
[TBL] [Abstract][Full Text] [Related]
10. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
[TBL] [Abstract][Full Text] [Related]
11. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
12. Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer.
Kikuchi S; Nishimura R; Osako T; Okumura Y; Nishiyama Y; Toyozumi Y; Arima N
Anticancer Res; 2013 Sep; 33(9):3891-7. PubMed ID: 24023325
[TBL] [Abstract][Full Text] [Related]
13. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
14. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
16. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homologue 2 expression in breast carcinoma smears in relationship with p53, Ki-67 and other prognostic parameters.
Athanassiadou AM; Tsipis A; Patsouris E; Gonidi M; Nicolopoulou-Stamati P; Chelidonis G; Athanassiadou P
Acta Cytol; 2011; 55(2):180-6. PubMed ID: 21325804
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer in young women: prognostic factors and clinicopathological features.
Aryandono T; Harijadi ; Soeripto
Asian Pac J Cancer Prev; 2006; 7(3):451-4. PubMed ID: 17059343
[TBL] [Abstract][Full Text] [Related]
19. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
20. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
